Vetted by NeuralPress's Multi-Agent Verifier for strict factual validity and event relevance. Our compliance engine cross-checks and filters search results to ensure zero false correlations or misleading content.
Primary Sources
AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials - WIRED
Google DeepMind’s AlphaFold has already revolutionized scientists’ understanding of proteins. Now, the ability of the platform to design safe and effective drugs is about to be put to the test.Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize–winning AI technology. “We're gearing up to go into the clinic,” Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. “It's going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.”Jaderberg did not elaborate on the timeline, but it’s later than the company had planned to initiate human studies. Last year, CEO Demis Hassabis said it would have AI-designed drugs in clinical trials by the end of 2025.Isomorphic Labs was founded in 2021 as a spinoff from Alphabet’s AI research subsidiary, Google DeepMind. The company uses DeepMind’s AlphaFold, a groundbreaking AI platform that predicts protein structures, for drug discovery.Built from 20 different amino acids, proteins are essential for all living organisms. Long strings of amino acids link together and fold up to make a protein’s three-dimensional structure, which dictates the protein’s function. Researchers had tried to predict protein structures since the 1970s, but this was a painstaking process given the astronomically high number of possible shapes a protein chain can take.That changed in 2020, when DeepMind’s Hassabis and John Jumper presented stunning results from AlphaFold 2, which uses deep-learning techniques. A year later, the company released an open-source version of AlphaFold available to anyone.In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists’ understanding of proteins even further. It moved beyond modeling proteins in isolation to predicting other important molecules, such as DNA and RNA, and their interactions with proteins.“This is exactly what you need for drug discovery: You need to see how a small molecule is going to bind to a drug, how strongly, and also what else it might bind to,” Hassabis told WIRED at the time.Since its release, the AlphaFold platform has been able to predict the structure of virtually all the 200 million proteins known to researchers and has been used by more than 2 million people from 190 countries. The breakthrough earned Hassabis and Jumper the Nobel Prize for chemistry in 2024, with the Nobel committee noting that Alp...
Google DeepMind CEO Demis Hassabis says "AI-designed drugs could ...
Google DeepMind CEO Demis Hassabis says AI could redesign drug discovery, with Isomorphic Labs aiming to cut timelines, reduce failures, and launch the first fully AI-designed drug trial by 2026. April 19, 2026 / 16:12 IST Story continues below Advertisement Remove Ad Artificial Intelligence Google DeepMind's Isomorphic Labs aims to speed up drug discoveryAI like AlphaFold 3 may design drugs and predict effectsFirst clinical trial of a fully AI-designed drug expected by 2026Did our AI summary help? Demis Hassabis, who leads Google DeepMind, has outlined a project that aims to change how medicines are developed. He said artificial intelligence could replace large parts of the traditional drug discovery process, which currently takes years and often fails before reaching patients.The project, called Isomorphic Labs, is focused on building systems that can design drugs using computational models instead of relying only on laboratory testing.What the project is trying to solveDrug development today is a long and expensive process. It takes an average of 10 years to develop a single drug and requires billions of dollars in investment. Data suggests that nearly 90 percent of drug candidates fail before reaching the market.Only one out of ten drugs entering clinical trials is approved for use. This means most of the time, years of research and funding do not result in a usable treatment.Story continues below AdvertisementHassabis said AI could help shorten this cycle by predicting how a drug will behave before physical experiments begin.How AI-led drug discovery may change the processThe effort builds on systems like AlphaFold, which can predict the structure of proteins. Isomorphic Labs is now working on extending this with newer models such as AlphaFold 3 and a broader system referred to as IsoDDE.These systems aim to design drug compounds, predict how they bind to proteins, and estimate their behavior in the human body. The company is currently running multiple drug programs in areas such as cancer and cardiovascular disease, in collaboration with Eli Lilly, Novartis, and Johnson & Johnson.The first clinical trial of a fully AI-designed drug is expected by 2026. If successful, it would mark a shift toward AI-led drug development, where parts of the process move from laboratories to computational systems. Invite your friends and family to sign up for MC Tech 3, our daily newsletter that breaks down the biggest tech and startup stories of the day Sarthak Sing...
AI-designed drugs can replace decades-long process: Demis Hassabis
Google DeepMind CEO Demis Hassabis said AI could speed up traditional drug discovery process, which currently takes several years and is often failure-prone. He noted DeepMind's Isomorphic Labs aims to design medicines using advanced models like AlphaFold and estimate their behaviour in the human body. The company expects the first clinical trial of a fully AI-designed drug by 2026.
AI Drug Discovery & Microbiome Research at IIT Madras - LinkedIn
Even Isomorphic Labs presents this as AI accelerating drug discovery ... trial-and-error → data-driven medicine. The big idea : Genomics was step 1 ...
